A late phase II study of S-1 for metastatic pancreatic cancer
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Uesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Self-citationUeno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 628
Self-citationUeno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 439
Ueno, H., Ikeda, M., Ueno, M., Mizuno, N., Ioka, T., Omuro, Y., Nakajima, T. E., & Furuse, J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2972-3 · Cited by 158
Self-citationS-1: a promising new oral fluoropyrimidine derivative
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902729412 · Cited by 101
“, 2002, 2003 [58,59] Pancreatic cancer – –”
BackgroundSchultheis, B., Strumberg, D., Bergmann, L., Graeven, U., Hanauske, A.-R., Lipp, R., Schuette, J., Saito, K., Scigalla, P., & Scheulen, M. E. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9665-x · Cited by 14
“In Phase 2 studies conducted in Japan, S-1 demonstrated antitumor activity in patients with metastatic pancreatic cancer, with an overall response rate of 21– 38% and a median survival time of 6–9 months [10, 11, 16, 17].”
Background
Metadata
- Authors
- Okusaka, T., Funakoshi, A., Furuse, J., Boku, N., Yamao, K., Ohkawa, S., & Saito, H.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2007-05-23
- Volume
- 61
- Issue
- 4
- Pages
- 615-621
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1972107936
- Cited by
- 169
- References
- 0
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.